What is Sitryx?
Sitryx operates at the vanguard of drug discovery, focusing on the critical role of energetic status in immune cell behavior. Founded by a consortium of six world-leading researchers, the company utilizes a proprietary scientific platform to develop novel treatments for chronic diseases. By targeting the metabolic pathways that govern immune responses, Sitryx aims to deliver transformative therapies that offer superior efficacy compared to traditional modalities. The firm's strategic headquarters in Oxford, UK, places it at the heart of a vibrant life sciences ecosystem, facilitating collaboration with academic institutions and global pharmaceutical entities alike.
How much funding has Sitryx raised?
Sitryx has raised a total of $69M across 2 funding rounds:
Series A
$30M
Other Financing Round
$39M
Series A (2018): $30M, investors not publicly disclosed
Other Financing Round (2023): $39M led by Oxford Sciences Enterprises, Sofinnova Partners, and Lilly
Key Investors in Sitryx
Oxford Sciences Enterprises
Oxford Science Enterprises is an independent, billion-pound investment company created in 2015 to found, fund and build transformational businesses via the company's unique partnership with the University of Oxford, the worlds #1 research university.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations.
Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines, focusing on areas such as diabetes, oncology, immunology, and neuroscience.
What's next for Sitryx?
With the recent injection of capital, Sitryx is well-positioned to accelerate its drug discovery pipeline and transition its lead candidates into more advanced stages of clinical development. The company's strategic roadmap emphasizes the expansion of its immuno-oncology portfolio, leveraging the expertise of its academic founders and the operational support of its investor syndicate. As the firm continues to refine its metabolic-focused therapeutic platform, it remains focused on achieving key clinical milestones that will validate its unique approach to treating immune-mediated conditions. The ongoing collaboration with global pharmaceutical leaders further enhances the company's ability to scale its research and bring innovative solutions to patients on a global level.
See full Sitryx company page
